Cargando…

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells

The low five-year survival rate for patients with acute myeloid leukemia (AML), primarily caused due to disease relapse, emphasizes the need for better therapeutic strategies. Disease relapse is facilitated by leukemic stem cells (LSCs) that are resistant to standard chemotherapy and promote tumor g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arvindam, Upasana Sunil, van Hauten, Paulien M.M., Schirm, Dawn, Schaap, Nicolaas, Hobo, Willemijn, Blazar, Bruce R., Vallera, Daniel A., Dolstra, Harry, Felices, Martin, Miller, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189652/ https://www.ncbi.nlm.nih.gov/pubmed/33097838 http://dx.doi.org/10.1038/s41375-020-01065-5

Ejemplares similares

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
por: Schmohl, Jörg U., et al.
Publicado: (2017)

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)
por: Hoogstad-van Evert, Janneke, et al.
Publicado: (2019)

Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo
por: Thordardottir, Soley, et al.
Publicado: (2017)

siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice
por: van der Waart, Anniek B., et al.
Publicado: (2015)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

CD34(+) progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg(null) mice
por: Van der Meer, Jolien M.R., et al.
Publicado: (2021)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8(+) T cells
por: Mousset, Charlotte M., et al.
Publicado: (2020)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

The Autoimmune Disorder Susceptibility Gene CLEC16A Restrains NK Cell Function in YTS NK Cell Line and Clec16a Knockout Mice
por: Pandey, Rahul, et al.
Publicado: (2019)

Good manufacturing practice production of CD34(+) progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia
por: de Jonge, P. K. J. D., et al.
Publicado: (2023)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
por: Vallera, Daniel A., et al.
Publicado: (2021)

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
por: Schmohl, Joerg U., et al.
Publicado: (2016)

Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
por: Spanholtz, Jan, et al.
Publicado: (2011)

Human CD34(+)-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8(+) T cell and NK cell responses in vitro and in vivo
por: van Eck van der Sluijs, Jesper, et al.
Publicado: (2023)

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
por: Myers, Jacob A., et al.
Publicado: (2022)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients
por: Hoogstad-van Evert, Janneke S., et al.
Publicado: (2018)

Clinically applicable CD34(+)-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses
por: van Eck van der Sluijs, Jesper, et al.
Publicado: (2021)

Unexpected Complication of a Multinodular Goitre
por: van Hauten, Paulien MM, et al.
Publicado: (2016)

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2020)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2021)

AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells
por: Gama, Sofia Mônaco, et al.
Publicado: (2023)

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

CLEC16A regulates splenocyte and NK cell function in part through MEK signaling
por: Pandey, Rahul, et al.
Publicado: (2018)

Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
por: Nersesian, Sarah, et al.
Publicado: (2019)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction
por: Mathew, Stephen O., et al.
Publicado: (2016)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8(+) T cells for adoptive immunotherapy
por: Mousset, Charlotte M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tblaujnb8cs534eull4ume98iv